Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $1.25 on Wednesday. The firm has a market capitalization of $7.13 million, a P/E ratio of -0.26 and a beta of 0.40. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The company has a fifty day moving average price of $2.24 and a 200-day moving average price of $4.54.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.